HemoShear Therapeutics Announces First Two Patients Dosed in Phase 2 Study of Oral Small Molecule HST5040 for Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA) prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
HemoShear Therapeutics Advances Second Novel Drug Target into Horizon Therapeutics plc Early Discovery Pipeline for Gout
- Second Milestone Achieved by HemoShear in Exclusive Drug Discovery Collaboration -
News provided by
Share this article
CHARLOTTESVILLE, Va., April 21, 2021 /PRNewswire/
HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has identified a second drug target for the treatment of gout under its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP) that was established in January 2019. Leveraging its proprietary
REVEAL-Tx™ disease modeling platform, HemoShear has earned two milestone payments to date in accordance with the Horizon exclusive drug discovery agreement. Each milestone acknowledges the validation of a novel drug target and its advancement to a subsequent stage in Horizon s early discovery pipeline.
HemoShear Therapeutics Raises $40 Million in Series A Financing to Advance Rare Disease Portfolio
~ Suvretta Capital Leads Financing with Janus Henderson Investors and Adage Capital Management Joining Syndicate
News provided by
Share this article
Share this article
CHARLOTTESVILLE, Va., Feb. 10, 2021 /PRNewswire/ HemoShear Therapeutics, Inc., a clinical stage company developing treatments for rare metabolic disorders, has raised $40 million in a Series A financing. Suvretta Capital led the financing along with Janus Henderson Investors, Adage Capital Management LP and other private investors. The Series A funding will enable the company to complete a phase 2 study of its lead compound, HST5040, for the treatment of methylmalonic acidemia (MMA) and propionic acidemia (PA), as well as fund future clinical studies and earlier stage programs.
5 Questions With… 2020 Recap
In 2020 we introduced a new series titled “5 Questions With…” in an effort to spotlight individuals from across the BioHealth Capital Region and beyond. Providing this platform has allowed us to help share the stories of industry peers and show that there isn’t a single “right” way to becoming an industry success.
As the year wraps up and we look forward to 2021, we are also looking back to the 30 guests we’ve featured in this series. From CFOs to Scientists, Veterans to Venture Capitalists, Company Founders to Leadership who recently joined their current companies, and everyone inbetween.